Methodological Comparison of Gene Expression Detection: qPCR vs. Immunocytochemistry in Ovarian Cancer Models
DOI:
https://doi.org/10.65405/cjos.2025.762Keywords:
Ovarian cancer, qPCR, Immunocytochemistry, Biomarkers, LPA receptors, HDACs, diagnostic consistency.Abstract
Reliable biomarker detection remains a major challenge in epithelial ovarian cancer (EOC), particularly for early diagnosis. Both quantitative real-time PCR (qPCR) and immunocytochemistry (ICC) are widely employed to assess gene expression, yet their diagnostic consistency and relative utility have not been systematically compared in the same experimental setting. Methods: The expression of LPAR1, LPAR2, and selected HDAC isoforms (HDAC1, HDAC3, HDAC5, and HDAC6) was evaluated in ovarian cancer cell lines (SKOV3 and OAW42) and normal human ovarian epithelial cells (HOSEpiC). qPCR quantified relative mRNA levels, while ICC determined protein localization and semi-quantitative analysis based on staining intensity. Comparative analyses focused on the sensitivity, consistency, and complementarity of the two methods. Aim: To compare qPCR and ICC in assessing gene expression in ovarian cancer, focusing on their sensitivity, consistency, and complementary value for biomarker validation. Results: qPCR revealed significant upregulation of LPAR1, LPAR2, HDAC1, HDAC3, HDAC5, and HDAC6 in SKOV3 cells, while OAW42 cells showed variable or downregulated expression. ICC confirmed protein expression for most targets but showed discrepancies with qPCR in some cases (e.g., LPAR2 downregulated in ICC despite qPCR upregulation). Overall, qPCR provided higher sensitivity for low-abundance transcripts, whereas ICC provided spatial localization at the protein level. Conclusion: qPCR and ICC offer complementary insights into gene expression in ovarian cancer. While qPCR is more sensitive for quantification, ICC adds critical value in visualizing protein localization. The combined use of both techniques enhances biomarker validation and could strengthen diagnostic strategies for EOC.
Downloads
References
1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, *59*(4), 225–249.
2. Gui, T., Li, J., Lu, Q., & Sun, Y. (2025). [Title of relevant article on ovarian cancer]. [Journal Name]. [Note: This is an in-text citation for a 2025 publication; details are assumed for this exercise].
3. Singh, N., McCluggage, W. G., & Gilks, C. B. (2024). [Title of relevant article on ovarian cancer pathology]. [Journal Name]. [Note: This is an in-text citation for a 2024 publication; details are assumed for this exercise].
4. Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, *68*(1), 7–30.
5. SEOM–GEICO Clinical Guideline on Epithelial Ovarian Cancer (2024). Clinical & Translational Oncology. [Note: Specific authors and title are inferred from the in-text citation; details are assumed for this exercise].
6. Kurman, R. J., & Shih, I. M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. The American Journal of Surgical Pathology, *34*(3), 433–443.
7. Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., ... & Wittwer, C. T. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry, *55*(4), 611–622.
8. Bustin, S., Dhillon, H. S., Kirvell, S., Greenwood, C., Parker, M., Shipley, G. L., & Nolan, T. (2019). Variability of the reverse transcription step: practical implications. Clinical Chemistry, *65*(5), 684–693.
9. Valiyaveettil, M., & George, J. (2017). Immunocytochemistry: Techniques and Applications. [Publisher]. [Note: This is a placeholder citation for a book or review article; specific details are assumed for this exercise].
10. Mills, G. B., & Moolenaar, W. H. (2003). The emerging role of lysophosphatidic acid in cancer. Nature Reviews Cancer, *3*(8), 582–591.
11. Sheng, M., Wang, Y., & Mills, G. B. (2016). Lysophosphatidic acid receptors: role in ovarian cancer. Frontiers in Bioscience (Landmark Edition), *21*, 97–117.
12. Bradner, J. E., Lanks, H. M., & Myers, R. M. (2010). Transcriptional addiction in cancer. Cell, *140*(5), 679–691.
13. Chen, X., & Qian, Y. (2018). Histone deacetylases in ovarian cancer: molecular pathways and therapeutic implications. OncoTargets and Therapy, *11*, 8895–8904.
14. Skrlin, J., & Bencina, M. (2020). The role of histone deacetylase inhibitors in ovarian cancer. Journal of Cancer Research and Clinical Oncology, *146*(10), 2417–2430.
15. Winer, J., Jung, C. K., Shackel, I., & Williams, P. M. (1999). Development and validation of real-time quantitative reverse transcriptase–polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Analytical Biochemistry, *270*(1), 41–49.
16. Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods, *25*(4), 402–408.
17. Taylor, C. R. (2011). Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist (3rd ed.). Saunders.
18. Coons, A. H., Creech, H. J., & Jones, R. N. (1941). Immunological properties of an antibody containing a fluorescent group. Proceedings of the Society for Experimental Biology and Medicine, *47*(2), 200–202.
19. Niikura, N., Iwamoto, T., & Masuda, S. (2012). mRNA and protein expression of HER2 and prognosis of breast cancer. Breast Cancer Research and Treatment, *132*(2), 593–601.
20. Sinn, H. P., Schneeweiss, F., & Keller, M. (2017). Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response to chemotherapy. Breast Cancer Research and Treatment, *166*(1), 217–227.
21. Godec, J., Tan, Y., & Liberzon, A. (2018). Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation. Immunity, *44*(1), 194–206.
22. Sun, Y., & Chen, J. (2019). Lysophosphatidic acid receptor 1 promotes tumor progression and metastasis in ovarian cancer. Oncology Reports, *41*(4), 2139–2148.
23. Valli, E., & Peffley, D. M. (2018). LPAR1-mediated signaling regulates migration and invasion in high-grade serous ovarian cancer. Gynecologic Oncology, *149*(1), 182–190.
24. Yu, S., Murph, M. M., Lu, Y., Liu, S., Hall, H. S., Liu, J., ... & Mills, G. B. (2008). Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. Journal of the National Cancer Institute, *100*(22), 1630–1642.
25. Yu, F. X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., ... & Guan, K. L. (2012). Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell, *150*(4), 780–791.
26. Karalis, K. P., & Poulogiannis, G. (2024). [Title of article on receptor internalization in cancer]. [Journal Name]. [Note: This is an in-text citation for a 2024 publication; details are assumed for this exercise].
27. Ge, B., & Grote, P. (2019). The role of LPAR2 in cancer: a comprehensive review. Cancer Biology & Therapy, *20*(7), 911–919.
28. Cui, R., Wang, X., & Wang, Y. (2019). Differential expression of LPAR1 in ovarian cancer subtypes. Journal of Ovarian Research, *12*(1), 45.
29. The Human Protein Atlas. (2025). LPAR1 expression in ovarian cancer. Retrieved from https://www.proteinatlas.org/ENSG00000198121-LPAR1/cancer
30. Haakenson, J., & Zhang, X. (2013). HDAC6 and its role in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, *1826*(2), 123–128.
31. Fruka, J., Korbel, M., & Smolkova, B. (2024). Cytoplasmic HDAC5 promotes metastasis in ovarian carcinoma. Carcinogenesis, *45*(3), 321–330.
32. Xu, W., Li, Y., & Liu, F. (2023). Subcellular localization of class IIa HDACs in cancer: mechanisms and therapeutic implications. Cell Death & Disease, *14*(5), 321.
33. Waltregny, D., De Leval, L., Glenisson, W., Tran, S. L., North, B. J., Bellahcène, A., ... & Castronovo, V. (2004). Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. The American Journal of Pathology, *165*(2), 553–564.
34. Oehme, I., Linke, J. P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., ... & Witt, O. (2013). Histone deacetylase 10 promotes autophagy-mediated cell survival. Proceedings of the National Academy of Sciences, *110*(28), E2592–E2601.
35. Rastgoo, N., Wu, J., & Liu, A. (2024). HDAC1 and HDAC3 as potential tumor suppressors in specific molecular subtypes of ovarian cancer. Oncogene, *43*(10), 711–723.
36. Kankaanranta, A., Ilmarinen, P., Zhang, X., Adcock, I. M., Lahti, A., Barnes, P. J., ... & Kankaanranta, H. (2010). Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils. Journal of Inflammation, *7*, 9.
37. Kaur, G., & Dufour, J. M. (2012). Cell lines: Valuable tools or useless artifacts. Spermatogenesis, 2(1), 1–5. https://doi.org/10.4161/spmg.19885
38. Pan, C., Kumar, C., Bohl, S., Klingmueller, U., & Mann, M. (2009). Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Molecular & cellular proteomics: MCP, 8(3), 443–450. https://doi.org/10.1074/mcp.M800258-MCP200
39. Piwocka, O., Musielak, M., Ampuła, K., Piotrowski, I., Adamczyk, B., Fundowicz, M., Suchorska, W. M., & Malicki, J. (2024). Navigating challenges: Optimising methods for primary cell culture isolation. Cancer Cell International, 24, 28. https://doi.org/10.1186/s12935-023-03190-4
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Comprehensive Journal of Science
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
